Intravitreal Therapy in Adults Aged &#x2264;50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Retinal Diseases

Real-world effect of vitrectomy combined with intravitreal conbercept for treatment of vitreous haemorrhage in proliferative diabetic retinopathy (QILIN I): a prospective cohort study

Br J Ophthalmol

Liu Y, Huang J, Ao M, Huang Y, Ma X, Han Q, Sun D, Zhong J, Qiu Q, Peng H, Wang Z, Ye J, Ma Z, Hao Y, Hu Y, Chang Q, Lu H, Li X, Liang J, Li S, Li J, Yu X, Yang L, Bi C, Li B, Zhang F, Wu R, Jin X, Zhou G, Liao M, Lei Y, Han H, Yan H

doi: 10.1136/bjo-2025-329066

Retinal Diseases

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

Br J Ophthalmol

Nguyen CT, Lassen RKB, Mæng MO, Lee C, Subhi Y, Vorum H, Wykoff CC, Ørskov M, Cehofski LJ

doi: 10.1136/bjo-2025-329273

Macular Diseases

Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes

BMC Ophthalmol

Konttinen A, Wirkkala J, Kubin AM, Ohtonen P, Hautala N

doi: 10.1186/s12886-026-05083-2

Macular DiseasesRetinal Diseases

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebneter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR, Swiss Retina Research Network

doi: 10.1007/s40123-025-01252-6

Macular Diseases

Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry

Ophthalmol Retina

Goncalves L, Hashimoto Y, Barthelmes D, Barry R, Pollreisz A, Wolff B, Toole LO, Ponsioen TL, Morros HB, Creuzot-Garcher C, Gillies M, Gabrielle PH

doi: 10.1016/j.oret.2026.04.007

Macular Diseases

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

Br J Ophthalmol

Chalkiadaki E, Sim YS, Williams O, Elder L, Addison PK, Hamilton RD, Nicholson L, Sivaprasad S, Heng LZ

doi: 10.1136/bjo-2025-328893

Glaucoma and Ocular Pressure

Childhood Angle-Closure: Etiology and Treatment Outcomes from a Large Series Spanning Over 20 Years

Ophthalmol Glaucoma

Seresirikachorn K, Vu DM, Perez AM, Thiamthat W, Peter Chang TC

doi: 10.1016/j.ogla.2026.05.005

Ophthalmology

Intravitreal Therapy in Adults Aged ≤50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

Related content

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Real-world effect of vitrectomy combined with intravitreal conbercept for treatment of vitreous haemorrhage in proliferative diabetic retinopathy (QILIN I): a prospective cohort study

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes

Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

Childhood Angle-Closure: Etiology and Treatment Outcomes from a Large Series Spanning Over 20 Years